REG - N4 Pharma PLC - Total Voting Rights
RNS Number : 2196ON4 Pharma PLC29 May 202029 May 2020
N4 Pharma plc("N4 Pharma", the "Company" or the "Group")
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the Company's issued ordinary share capital as at the date of this announcement comprises 152,193,787 ordinary shares, with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 152,193,787.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO
Via Scott PR
Allenby Capital Limited
James Reeve/Asha Chotai
Tel: +44(0)203 328 5656
Turner Pope Investments (TPI) Ltd
Andrew Thacker
Tel: +44(0)20 3657 0050
Scott PR
Georgia Smith
Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDTVRKKFBQFBKKCPB
Recent news on N4 Pharma
See all newsREG - N4 Pharma PLC - Posting of Annual Report & Notice of AGM
AnnouncementRCS - N4 Pharma PLC - N4 Pharma Webinar on SRI Collaboration
AnnouncementREG - N4 Pharma PLC - Collaboration Agreement with SRI International Inc
AnnouncementREG - N4 Pharma PLC - Final Results
AnnouncementREG - N4 Pharma PLC - Oral Delivery Update
Announcement